Details

Autor(en) / Beteiligte

• Thompson, P.
• Cardona, K.
• Russell, M.
• Badell, I. R.
• Shaffer, V.
• Korbutt, G.
• Rayat, G. R.
• Cano, J.
• Song, M.
• Jiang, W.
• Strobert, E.
• Rajotte, R.
• Pearson, T.
• Kirk, A. D.
• Larsen, C. P.

Titel

CD40‐Specific Costimulation Blockade Enhances Neonatal Porcine Islet Survival in Nonhuman Primates

Ist Teil von

• American journal of transplantation, 2011-05, Vol.11 (5), p.947-957

Ort / Verlag

Malden, USA: Blackwell Publishing Inc

Erscheinungsjahr

2011

Link zum Volltext

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• The widespread clinical implementation of alloislet transplantation as therapy for type 1 diabetes has been hindered by the lack of suitable islet donors. Pig‐to‐human islet xenotransplantation is one strategy with potential to alleviate this shortage. Long‐term survival of porcine islets has been achieved using CD154‐specific antibodies to interrupt the CD40/CD154 costimulation pathway; however, CD154‐specific antibodies seem unlikely candidates for clinical translation. An alternative strategy for CD40/CD154 pathway interruption is use of CD40‐specific antibodies. Herein, we evaluate the ability of a chimeric CD40‐specific monoclonal antibody (Chi220) to protect islet xenografts. Neonatal porcine islets (∼50 000 IEQ/kg) were transplanted intraportally into pancreatectomized diabetic macaques. Immunosuppression consisted of induction therapy with Chi220 and the IL‐2 receptor‐specific antibody basiliximab, and maintenance therapy with sirolimus and the B7‐specific fusion protein belatacept. Chi220 effectively promoted xenoislet engraftment and survival, with five of six treated recipients achieving insulin‐independent normoglycemia (median rejection‐free survival 59 days; mean 90.8 days, maximum 203 days). No thromboembolic phenomena were observed. CD40 represents a promising alternative to CD154 as a therapeutic target, and the efficacy of CD40‐specific antibodies in islet xenotransplantation warrants further investigation. CD40‐specific costimulation blockade can substitute for CD154‐specific therapies to protect neonatal porcine islet xenografts.